Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | NK-cell enhancement: TRAIL variant

Michael O’Dwyer • 18 May 2020
COMy Virtual 2020
B-Cell Lymphoma Lymphoma Antibodies CAR-T NK-Cell Therapy

Michael O’Dwyer, MD, PhD, National University of Ireland, Galway, Ireland, discusses the incorporation of a TRAIL variant into NK-cells. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Michael O’Dwyer

3:31
Genomic and transcriptomic analysis of R/R myeloma in the Phase III BELLINI study
Michael O’Dwyer • 30 Nov 2020
5:14
Current myeloma cellular therapy landscape and horizon scan
Michael O’Dwyer • 30 Nov 2020
2:01
Cellular therapy: NK-cells as a model
Michael O’Dwyer • 21 May 2020
4:00
Immunotherapies for the treatment of high-risk MM
Michael O’Dwyer • 18 May 2020

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals